General Information of Drug (ID: DMM5VTA)

Drug Name
Dutogliptin Drug Info
Synonyms Dutogliptin tartrate; PHX-1004; PHX-1149; PHX-1149T; DPP IV inhibitors (diabetes), Phenomix; DPP IV program (diabetes), Phenomix
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 3 [1]
Cross-matching ID
PubChem CID
11253490
CAS Number
CAS 852329-66-9
TTD Drug ID
DMM5VTA

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Saxagliptin DMGXENV Type-2 diabetes 5A11 Approved [3]
Sitagliptin DMGDKXN Cystic fibrosis CA25 Approved [4]
Alogliptin DM8WI3R Type-2 diabetes 5A11 Approved [5]
Linagliptin DMWFJTR Non-insulin dependent diabetes 5A11 Approved [6]
Vildagliptin DMYN59P Type-2 diabetes 5A11 Approved [7]
Dapagliflozin Propanediol; Saxagliptin Hydrochloride DM34TXO Type-2 diabetes 5A11 Approved [8]
Anagliptin DMJXIC9 Type-2 diabetes 5A11 Approved [9]
SaxaDapa FDC DMAPRWV Diabetic complication 5A2Y Phase 3 [10]
LC-150444 DM09RKB Type-2 diabetes 5A11 Phase 3 [11]
MK-3102 DM3PSUF Type-2 diabetes 5A11 Phase 3 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dipeptidyl peptidase 4 (DPP-4) TTDIGC1 DPP4_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT00690638) Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
2 Dutogliptin, a selective DPP4 inhibitor, improves glycaemic control in patients with type 2 diabetes: a 12-week, double-blind, randomized, placebo-controlled, multicentre trial. Diabetes Obes Metab. 2010 Apr;12(4):348-55.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol Ther. 2009 Oct;124(1):113-38.
5 Clinical pipeline report, company report or official report of Takeda (2009).
6 Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
7 Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9 Diabetes Treatment. Diabetes Care. 2009 March; 32(3): e25-e30.
10 Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes. Cardiol Rev. 2010 Jul-Aug;18(4):213-7.
11 Clinical pipeline report, company report or official report of ShangHai APIs Chemical.
12 Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. J Med Chem. 2014 Apr 24;57(8):3205-12.